PRDX3 and diabetic kidney disease: The SGLT2 inhibitor empagliflozin has been shown to alleviate diabetic nephropathy by restoring the expression of peroxiredoxin 3 (Prdx3) and reducing the levels of ROS and mitochondrial ROS in a diabetic (db/db) mouse model [191].